1ISG-009 Economic impact of aflibercept optimisation for the treatment of eye-related conditions

BACKGROUND: Aflibercept is indicated for adults in the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME) or myopic choroidal neovascularisation (CNV). PURPOSE: To...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Garciadeparedes-Esteban, JC, Gil-Sierra, MD, Rios-Sanchez, E, Camean-Castillo, M, Diaz-Navarro, J, Rey, EJ Alegre-Del, Lopez-Vallejo, J, Martinez-Diaz, C, Palomo-Palomo, C, Briceño-Casado, MDP, Borrero-Rubio, JM
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 1: Introductory statements and governance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535176/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars